Russia is searching for an association with India for creating COVID-19 antibody Sputnik V, Kirill Dmitriev, the CEO of the Russian Direct Investment Fund (RDIF), said on Thursday.

Russian President Vladimir Putin had declared that his nation has built up the world's first immunization against COVID-19, which works "adequately" and structures a "steady resistance" against the sickness.

Sputnik V has been created by the Gamaleya Research Institute of Epidemiology and Microbiology, alongside the RDIF. The immunization has not been tried in Phase 3 or bigger clinical preliminaries.

Tending to an online press preparation, Dmitriev said a few countries are keen on the creation of the antibody from nations in Latin America, Asia, and the Middle East.

"The creation of immunization is a significant issue. As of now, we are searching for an association with India. We accept that they are fit for creating the Gamaleya antibody and it is critical to express that those organizations to deliver the immunization will empower us to cover the interest that we have," he said.

Dmitriev said Russia is anticipating universal collaboration.

"We will do clinical preliminaries in Russia as well as in the UAE, Saudi Arabia, presumably in Brazil and India. We are wanting to create the immunization over five nations and there is an appeal from Asia, Latin America, Italy, and different pieces of the world concerning the conveyance of the antibody," he said.

Alexander Ginsburg, the head of the Gamaleya Research Institute of Epidemiology and Microbiology and an academician at the Russian Academy of Sciences, said more than 20,000 individuals have partaken in the clinical preliminaries of antibodies and medications, in light of human adenoviruses or human adenoviral vectors.

"Immunizations don't contain live human adenoviruses, however human adenovirus vectors, that is, human infections that can't duplicate in the body and are sheltered," he said.

The Sputnik V antibody comprises two shots that utilization various adaptations of adenoviruses - infection types, some of which cause the normal cold - that the producers have designed to convey the quality for the surface protein of SARS-CoV-2 that causes COVID-19.

"The methodology of the Gamaleya Institute with the antibody, utilizing two human adenoviruses serotypes: number 5 (Ad5) and number 26 (Ad26), has an unmistakable favorable position over the one-vector approach utilized by different engineers," Ginsburg said.